Nasdaq:TBPH
Theravance Biopharma, Inc.
A clinical-stage biopharmaceutical firm developing next-generation therapies for oncology, immunology, and rare disease indications.
Key Metrics
Investment Thesis
Bull Case
Investors may be attracted by the potential value creation from a breakthrough asset or successful partnership deal that could turn the current losses into significant profits. The company's focus on serious unmet needs offers high growth potential in oncology and immunology where market sizes are substantial. Strategic collaborations could provide immediate liquidity through upfront payments and milestones to offset the $56.4M annual cash burn.
Bear Case
The persistent net losses of over $56M annually combined with a massive retained earnings deficit of nearly $1B indicate severe financial distress and high dilution risk. With total liabilities exceeding $178M against only $38.6M in cash, the company faces a precarious liquidity position requiring continuous capital raising. The clinical-stage nature of the business carries extreme binary risks that could lead to total loss of invested capital if key trials fail.
About Theravance Biopharma, Inc.
Theravance Biopharma Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapies for serious unmet medical needs in oncology, immunology, and rare diseases. The company serves global markets with a pipeline of proprietary assets aimed at addressing critical patient populations through innovative drug discovery and development programs.
Analysis
Management Discussion
The company reported a net loss of $56.4M in 2024, consistent with the previous year's loss of $55.2M, while revenue grew to $64.4M from $57.4M in 2023. This growth was achieved despite elevated operating expenses including $69.2M in general and administrative costs and $37.6M allocated to research and development.
Industry Overview
The biopharmaceutical industry is characterized by high barriers to entry, long development cycles, and significant regulatory hurdles before products reach market. Companies in this sector typically operate with negative free cash flow during the development phase while investing heavily in R&D to secure exclusive patent rights. Market success depends on demonstrating clinical efficacy and safety compared to existing standard-of-care treatments.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $51.3M | $57.4M | $64.4M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $51.3M | $57.4M | $64.4M |
| Operating Expenses | $143.3M | $113.5M | $111.3M |
| Operating Income | $-92.0M | $-56.0M | $-46.9M |
| R&D | $63.4M | $40.6M | $37.6M |
| G&A | $67.1M | $70.1M | $69.2M |
| Stock-Based Comp | $39.7M | $25.4M | $21.4M |
| Depreciation | $2.6M | $1.9M | $1.6M |
| Other OpEx | $12.8M | $2.7M | $4.5M |
| Non-Operating Income | $-858.0K | $6.8M | $2.3M |
| Interest Expense | $6.4M | $2.4M | — |
| Pre-Tax Income | $-92.8M | $-49.3M | $-44.6M |
| Income Tax | $9.0K | $5.9M | $11.8M |
| Continuing Ops | $-92.8M | $-55.2M | $-56.4M |
| Discontinued Ops | $965.0M | $0 | $0 |
| Net Income | $872.1M | $-55.2M | $-56.4M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $872.1M | $-55.2M | $-56.4M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $353.5M | $133.5M | $161.1M |
| Cash & Equivalents | $298.2M | $39.5M | $37.8M |
| Other Current Assets | $55.3M | $94.0M | $123.3M |
| Long-Term Assets | $253.9M | $248.5M | $193.1M |
| PP&E (Net) | $11.9M | $9.1M | $7.4M |
| Operating Leases | $40.1M | $36.3M | $28.4M |
| Other LT Assets | $201.9M | $203.1M | $157.3M |
| Total Assets | $607.4M | $382.0M | $354.2M |
| Current Liabilities | $28.7M | $24.8M | $32.1M |
| Accounts Payable | $1.6M | $1.5M | $2.2M |
| Current Leases | $6.8M | $3.9M | $10.7M |
| Deferred Revenue | $24.0K | — | — |
| Taxes Payable | — | — | $5.9M |
| Other Current Liab | $20.4M | $19.3M | $13.3M |
| Long-Term Liabilities | $136.9M | $144.2M | $146.5M |
| LT Operating Leases | $45.4M | $45.2M | $39.1M |
| Other LT Liab | $91.3M | $99.0M | $107.4M |
| Total Liabilities | $165.6M | $169.0M | $178.6M |
| Shareholders' Equity | $441.8M | $213.0M | $175.5M |
| Paid-In Capital | $1.30B | $1.12B | $1.14B |
| Retained Earnings | $-853.9M | $-909.1M | $-965.5M |
| AOCI | $-15.0K | $-65.0K | $7.0K |
| Total L&E | $607.4M | $382.0M | $354.2M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $872.1M | $-55.2M | $-56.4M |
| Non-Cash Adjustments | $-1.04B | $25.8M | $50.3M |
| Working Capital Changes | $-14.2M | $2.4M | $-5.5M |
| Cash from Operations | $-187.0M | $-27.0M | $-11.5M |
| Cash from Investing | $1.15B | $-32.7M | $12.3M |
| Share Buybacks | $128.8M | $197.1M | $445.0K |
| Cash from Financing | $-758.8M | $-198.9M | $-2.5M |
| FX Effect | $0 | $0 | $0 |
| Net Change in Cash | $208.2M | $-258.6M | $-1.7M |
| Beginning Cash | $90.8M | $299.0M | $40.4M |
| Ending Cash | $299.0M | $40.4M | $38.6M |
Frequently Asked Questions
How does Theravance Biopharma, Inc. make money?
The company's revenue is primarily derived from its clinical-stage asset portfolio in oncology, which includes collaborations with major pharmaceutical partners. Additional revenue streams include non-oncology assets focusing on immunology and rare diseases, supported by ongoing research and development expenditures of $37.6M.
What are the main risks for TBPH?
High risk of clinical trial failure or regulatory rejection for its late-stage development assets given the $37.6M annual R&D spend. Potential delays in obtaining marketing approval from global health authorities impacting revenue recognition timelines. Dependence on external funding sources due to significant cash burn and a retained earnings deficit of $965.5M.
What is TBPH's competitive advantage?
First-in-class or best-in-class novel mechanisms of action that differentiate its pipeline from competitors in crowded therapeutic areas. Strong strategic partnerships with leading pharmaceutical companies providing commercialization support and milestone payments. A diverse portfolio spanning oncology, immunology, and rare diseases mitigating reliance on a single asset class.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.